Evaluation of Surrogate Endpoints Using a Meta-Analysis Approach with Individual Patient Data: Summary of a Gastric Cancer Meta-Analysis Project
Author:
Oba Koji,Paoletti Xavier
Publisher
Springer Singapore
Reference42 articles.
1. Alonso A, Van der Elst W, Molenberghs G, Buyse M, Burzykowski T, et al. On the relationship between the causal-inference and meta-analytic paradigms for the validation of surrogate endpoints. Biometrics. 2015;71:15–24.
2. Alonso A, Molenberghs G. Surrogate marker evaluation from an information theory perspective. Biometrics. 2007;63:180–6.
3. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001;69:89–95.
4. Bonini S, Eichler H-G, Wathion N, Rasi G. Transparency and the European Medicines Agency—sharing of clinical trial data. New Engl J Med. 2014;371:2450–2.
5. Broglio KR, Berry DA. Detecting an overall survival benefit that is derived from progression-free survival. J Natl Cancer Inst. 2009;101:1642–9.